KOVALTRY® is covered by all major national insurance companies

Includes Express Scripts, CVS/Caremark, OptumRx, Prime Therapeutics, Magellan, Aetna, Humana, UnitedHealthcare, Anthem, and Cigna

Reimbursement Support, Coverage, Financial and Affordability Solutions

$0 Co-Pay Program*†: Eligible commercially insured patients can pay as low as $0 per prescription, regardless of income. (Up to $12,000 in co-pay assistance per year.)

Free Trial Program ‡§: Talk to your patients about requesting a Free Trial of Kovaltry with vial adapter

Patient Loyalty Program†§ll: Eligible patients can receive Kovaltry at no cost if they experience gaps or changes with insurance coverage

Live Helpline Support: You or your patients can call for answers to any insurance coverage questions

Click here to prescribe Kovaltry to your patient Click here to submit a $0 prescription claim under your patient’s medical benefit
CALL 1-800-288-8374 NOW!
9:00 AM–6:00 PM (ET) Monday–Friday.
Multiple languages available, including Spanish.

*Co-pay program support is available for up to 1 year. Can include any out-of-pocket prescription costs, such as co-pay and co-insurance.

Patients who are enrolled in any type of government insurance are not eligible. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.

Participation in the Kovaltry Free Trial Program is limited to 1 time only per product (patients currently using Kovaltry are not eligible for a Free Trial of their current product). The Free Trial Program includes 1 month supply up to a maximum of 40,000 IU. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.

§The medication provided through this program is at no cost to the patient and is not contingent on future use of this medication. Reselling or billing any third party for free product provided by this program is prohibited by law

INDICATIONS

KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

KOVALTRY is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY if symptoms occur and seek immediate emergency treatment.

KOVALTRY may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation has occurred following administration of KOVALTRY. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥3%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and headache, pyrexia, and pruritus.

For additional important risk and use information, please see full Prescribing Information.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© 2021 Bayer.   All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.
Access Services by Bayer is a trademark of Bayer.
Advate is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

Site Last Modified 02/2021